We are live on ! Find out more
ASMB icon

Assembly Biosciences

44 hedge funds and large institutions have $7.09M invested in Assembly Biosciences in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

38% more funds holding

Funds holding: 3244 (+12)

0.42% less ownership

Funds ownership: 1.51%1.1% (-0.42%)

16% less capital invested

Capital invested by funds: $8.44M → $7.09M (-$1.35M)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

60% less call options, than puts

Call options by funds: $2K | Put options by funds: $5K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
44
Holders Change
+12
Holders Change %
+37.5%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
16
Increased
7
Reduced
9
Closed
4
Calls
$2K
Puts
$5K
Net Calls
-$3K
Net Calls Change
-$12K

ASMB Hedge Fund Activity: Q4 2023 in Review

44 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2023, worth a combined $7.09M — down 16% from $8.44M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ASMB positions and 4 closed out — a net gain of 12 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $570K. The largest seller was Alerce Investment Management, exiting entirely with an estimated $1.97M sold.

  • 44 institutional investors held Assembly Biosciences (ASMB) as of Q4 2023, up from 32 in Q3 2023.
  • Funds reported $7.09M of Assembly Biosciences stock for Q4 2023, down 16% quarter-over-quarter.
  • 16 funds opened new Assembly Biosciences positions in Q4 2023 and 4 closed out, a net change of +12 holders.
  • The largest Assembly Biosciences buyer in Q4 2023 was Anson Funds Management, an estimated $570K added.
  • The largest Assembly Biosciences seller in Q4 2023 was Alerce Investment Management, an estimated $1.97M sold.

Based on aggregated 13F filings for Q4 2023.